Colorado Springs, Colo. – March 15, 2021 – Folium Biosciences has submitted a novel food application to the UK Food Standards Agency (FSA) for the validation of its hemp-derived 0.0% THC broad-spectrum CBD (cannabidiol) oil, to ensure CBD Highest Quality Ingredients. The application was submitted on behalf of Folium Biosciences Europe B.V. and a consortium of several UK-based CBD customer partners of the company.
Folium submitted the application in response to the FSA’s 2020 requirement that all CBD products on the UK market must have a novel food application pass the validation phase of the review process before March 31, 2021. CBD food products that are not approved before the deadline will no longer be permitted to sell their products in the United Kingdom. The Folium application is unique in that it is based on a botanical extract rather than the purified CBD material used in other applications. This submission follows Folium’s core belief that the CBD industry must align its products and practices with what nature provides.
“Folium has a long track record of providing CBD ingredients of the highest quality, safety, consistency, and supply chain transparency, which has earned us approval from ethics committees and regulatory bodies around the world – even in countries with strict regulations regarding cannabinoids, such as Japan, Australia, New Zealand, and South America,” says Folium Chief Scientific Officer Vanesa Fernandez. “We are proud to continue demonstrating our global leadership in CBD as an active participant in regulatory advancement in the United Kingdom, and we look forward to taking the next step in the novel food regulatory process in the EU. It is in the interest of everyone in the CBD industry and the end customers we serve to make product quality and compliance our top priority.”
Folium’s application also included the company’s white-label finished products and UK customer finished products, along with the company’s broad-spectrum water-soluble hemp oil powder. The Novel Food approval thus ensures that Folium’s customer partners can maintain their market advantage with both white-label and custom formulations.
“Following the FSA guidelines is in many ways aligned with our ‘not all hemp is created equal’ promise, but perhaps most importantly because it unequivocally communicates that we are very intentional when it comes to delivering the best for our customers,” added Fernandez. “This novel food application is another essential step in ensuring that our customers and our products remain compliant in the European market.”
